Evotec Stock

Evotec Net Income 2024

Evotec Net Income

-115.8 M EUR

Ticker

EVT.DE

ISIN

DE0005664809

WKN

566480

In 2024, Evotec's profit amounted to -115.8 M EUR, a 38% increase from the -83.91 M EUR profit recorded in the previous year.

The Evotec Net Income history

YEARNET INCOME (undefined EUR)
2029e97.54
2028e111.22
2027e84.85
2026e19.95
2025e-25.97
2024e-115.8
2023-83.91
2022-175.66
2021215.51
20206.28
201938.07
201884.17
201723.48
201627.53
201516.52
2014-6.98
2013-25.4
20122.5
20116.7
20103.3
2009-45.5
2008-78.3
2007-11.2
2006-32.5
2005-33.6
2004-84.2

Evotec Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Evotec, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Evotec from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Evotec’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Evotec. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Evotec’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Evotec’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Evotec’s growth potential.

Evotec Revenue, EBIT and net profit per share

DateEvotec RevenueEvotec EBITEvotec Net Income
2029e1.71 B undefined0 undefined97.54 M undefined
2028e1.49 B undefined212.29 M undefined111.22 M undefined
2027e1.34 B undefined170.42 M undefined84.85 M undefined
2026e1.07 B undefined58.47 M undefined19.95 M undefined
2025e926.84 M undefined2.12 M undefined-25.97 M undefined
2024e817.03 M undefined-78.6 M undefined-115.8 M undefined
2023781.43 M undefined-42.5 M undefined-83.91 M undefined
2022751.45 M undefined20.85 M undefined-175.66 M undefined
2021618.03 M undefined41.68 M undefined215.51 M undefined
2020500.92 M undefined51.8 M undefined6.28 M undefined
2019446.44 M undefined74.51 M undefined38.07 M undefined
2018375.41 M undefined66.43 M undefined84.17 M undefined
2017263.77 M undefined37.91 M undefined23.48 M undefined
2016164.51 M undefined36.75 M undefined27.53 M undefined
2015127.68 M undefined-2.53 M undefined16.52 M undefined
201489.5 M undefined2.14 M undefined-6.98 M undefined
201385.9 M undefined4.1 M undefined-25.4 M undefined
201287.3 M undefined300,000 undefined2.5 M undefined
201180.1 M undefined5.8 M undefined6.7 M undefined
201055.3 M undefined1.7 M undefined3.3 M undefined
200942.7 M undefined-19.6 M undefined-45.5 M undefined
200839.6 M undefined-45.5 M undefined-78.3 M undefined
200732.9 M undefined-49.2 M undefined-11.2 M undefined
200667.4 M undefined-30.8 M undefined-32.5 M undefined
200579.8 M undefined-16.9 M undefined-33.6 M undefined
200472.7 M undefined-21.7 M undefined-84.2 M undefined

Evotec stock margins

The Evotec margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Evotec. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Evotec.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Evotec's sales revenue. A higher gross margin percentage indicates that the Evotec retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Evotec's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Evotec's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Evotec's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Evotec. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Evotec's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Evotec Margin History

Evotec Gross marginEvotec Profit marginEvotec EBIT marginEvotec Profit margin
2029e22.4 %0 %5.71 %
2028e22.4 %14.24 %7.46 %
2027e22.4 %12.7 %6.32 %
2026e22.4 %5.47 %1.87 %
2025e22.4 %0.23 %-2.8 %
2024e22.4 %-9.62 %-14.17 %
202322.4 %-5.44 %-10.74 %
202223.16 %2.77 %-23.38 %
202124.52 %6.74 %34.87 %
202025.1 %10.34 %1.25 %
201929.77 %16.69 %8.53 %
201829.84 %17.69 %22.42 %
201731.01 %14.37 %8.9 %
201635.59 %22.34 %16.73 %
201527.51 %-1.98 %12.94 %
201432.83 %2.39 %-7.8 %
201336.32 %4.77 %-29.57 %
201235.51 %0.34 %2.86 %
201143.7 %7.24 %8.36 %
201043.94 %3.07 %5.97 %
200943.09 %-45.9 %-106.56 %
200844.44 %-114.9 %-197.73 %
200724.32 %-149.54 %-34.04 %
200634.12 %-45.7 %-48.22 %
200536.34 %-21.18 %-42.11 %
200434.25 %-29.85 %-115.82 %

Evotec Aktienanalyse

What does Evotec do?

Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Evotec's Profit Margins

The profit margins of Evotec represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Evotec's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Evotec's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Evotec's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Evotec’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Evotec stock

How much profit has Evotec made this year?

Evotec has made -115.8 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by 38% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Evotec publish its earnings?

Evotec publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Evotec?

The profits of Evotec are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Evotec?

You can learn more about the earnings of Evotec by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Evotec pay?

Over the past 12 months, Evotec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Evotec is expected to pay a dividend of 0 EUR.

What is the dividend yield of Evotec?

The current dividend yield of Evotec is .

When does Evotec pay dividends?

Evotec pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Evotec?

Evotec paid dividends every year for the past 0 years.

What is the dividend of Evotec?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Evotec located?

Evotec is assigned to the 'Health' sector.

Wann musste ich die Aktien von Evotec kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Evotec from 11/10/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/10/2024.

When did Evotec pay the last dividend?

The last dividend was paid out on 11/10/2024.

What was the dividend of Evotec in the year 2023?

In the year 2023, Evotec distributed 0 EUR as dividends.

In which currency does Evotec pay out the dividend?

The dividends of Evotec are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Evotec stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Evotec

Our stock analysis for Evotec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Evotec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.